P
US9696302B2ActiveUtilityPatentIndex 83

Methods for isolating a target analyte from a heterogeneous sample

Assignee: DNAE GROUP HOLDINGS LTDPriority: Apr 21, 2010Filed: Sep 5, 2014Granted: Jul 4, 2017
Est. expiryApr 21, 2030(~3.8 yrs left)· nominal 20-yr term from priority
Inventors:DRYGA SERGEY AESCH VICTOR CCLARIZIA LISA-JO ANNADAMS EDDIE WUNG THEARITH HSITDIKOV RAVIL A
Y10T436/25375Y10T436/25G01N 2446/90G01N 33/54333C07K 1/22C12N 13/00C07K 16/1267C12Q 1/6806B01L 3/502738C12Q 1/68B01L 2300/0636G01N 33/53G01N 21/64G01N 33/5434C12Q 2565/629C12Q 2563/143
83
PatentIndex Score
10
Cited by
505
References
13
Claims

Abstract

The invention generally relates to methods of using compositions that include sets of magnetic particles, members of each set being conjugated to an antibody specific for a pathogen, and magnets to isolate a pathogen from a body fluid sample.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method for isolating pathogen from a heterogeneous sample, the method comprising:
 providing a vessel that contains a heterogeneous sample comprising pathogen, the vessel being coupled to a fluidic device that comprises a channel and a magnet; 
 introducing to the sample in the vessel a cocktail comprising a plurality of magnetic particles, conjugated to antibodies that bind said pathogen, thereby forming a mixture comprising antibody-bound pathogen particles; 
 flowing the mixture from the vessel through a channel in the fluidic device such that said magnetic particles attach to said magnet; and 
 separating antibody-bound pathogen attached to said magnet from other components in the sample. 
 
     
     
       2. The method of  claim 1 , further comprising the step of characterizing the pathogen. 
     
     
       3. The method of  claim 2 , wherein said characterizing step comprises identifying the pathogen. 
     
     
       4. The method of  claim 3 , wherein said identifying step is selected from sequencing nucleic acid derived from the pathogen and amplifying the nucleic acid. 
     
     
       5. The method of  claim 1 , wherein the sample is a blood sample. 
     
     
       6. The method of  claim 1 , wherein the particles are differentially labeled. 
     
     
       7. The method of  claim 6 , wherein the particles comprise is an optical label. 
     
     
       8. The method of  claim 7 , wherein the optical label is a fluorescent label. 
     
     
       9. The method of  claim 1 , wherein the antibodies are monoclonal antibodies. 
     
     
       10. The method of  claim 1 , wherein the antibodies are polyclonal antibodies. 
     
     
       11. The method of  claim 1 , wherein the pathogen is gram positive bacteria. 
     
     
       12. The method of  claim 1 , wherein the pathogen is gram negative bacteria. 
     
     
       13. The method of  claim 1 , wherein the pathogen is a virus.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.